HERA: 2 Years versus 1 Year of Adjuvant Trastuzumab at 8 Years of Follow-Up
OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. This unique conference provides many clinicians and scientists from around the world a forum for discussing critical issues in the prevention and management of breast cancer. Therefore, SABCS is targeted by many members of the clinical research community as the optimal time to unveil new clinical data. This creates an environment in which yearly published results from a plethora of ongoing clinical trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes.

Although SABCS currently offers online access to the vast majority of the poster and plenary presentations from the annual meeting, the absence of expert assessment concerning practical applications may yield confusion among community oncologists who are challenged almost daily to appropriately apply a multitude of scientific findings across diverse tumors. Thus, identification of those data sets with immediate or impending relevance to the delivery of quality breast cancer care, in conjunction with professional commentary to address resultant practice ambiguity, may prove vastly beneficial to those physicians who are unable to make the annual pilgrimage to San Antonio. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS, including expert perspectives on how these new evidence-based concepts can and should be incorporated into on- and off-protocol patient care. This activity will assist medical oncologists, radiation oncologists, breast/general surgeons, nurses and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

• Determine the optimal duration of trastuzumab administration in the adjuvant setting using recent clinical trial evidence evaluating 1 year of adjuvant trastuzumab versus 6 months or 2 years.
• Assess the long-term survival outcomes of patients receiving 1 year of adjuvant trastuzumab combined with chemotherapy in comparison to those receiving only chemotherapy, and consider this information in the management of early HER2-positive breast cancer.
• Evaluate the association between immune biomarkers and clinical responses to trastuzumab and pertuzumab as support for the potential use of combined HER2-targeted and immunomodulatory agents.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCSABCS2013/S/CE.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Lisa A Carey, MD
Professor in Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

George Sledge Jr, MD
Professor of Breast Cancer Research
Chair, Division of Hematology and Oncology
Physician-in-Chief
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Advisory Committee, Consulting Agreements and Speakers
Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi.

Edith A Perez, MD
Deputy Director at Large, Mayo Clinic Cancer Center
Group Vice Chair, Alliance of Clinical Trials in Oncology
Serene M and Frances C Durling Professor of Medicine
Mayo Clinic
Jacksonville, Florida

Contracted Research: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline.
George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Stanford, California

Advisory Committee: GlaxoSmithKline.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodex Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2013
Expiration date: May 2014
Key Papers on Adjuvant and Neoadjuvant Treatment of HER2-Positive Breast Cancer

To go directly to slides and commentary for this issue, [click here](#).

It’s now coming up on 8 years since that warm May day in Orlando when Dr George Sledge chaired the historic ASCO session during which the very first Phase III data sets confirming the benefit of adjuvant trastuzumab (T) with chemotherapy were unveiled. In San Antonio this past December we witnessed perhaps the final meaningful remnants of that generation of landmark studies while also getting a peek at the next set of relevant issues currently being addressed in ongoing trials. So to close out this year’s SABCS highlights series we look at several of the most intriguing presentations focused on the management of early HER2-positive disease.

1. Duration of adjuvant trastuzumab: HERA and PHARE trials

During a CME symposium our group hosted on the first night of the conference, the ever-mirthful Dr Sledge was tasked with reviewing this pragmatic topic, and to get things started the first slide he showed was a beautiful photo of the earth orbiting the sun. Of course, Dr Sledge’s visual metaphor related to the conclusion that he and most investigators had come to accept following the presentations of the HERA and PHARE data sets last October at the 2012 European Society for Medical Oncology Congress in Vienna — that 1 year of adjuvant T remains the optimal duration.

Both of these studies were updated in San Antonio. HERA, presented by Dr Martine Piccart-Gebhart, provided a definitive answer that 2 years of T is not better than 1. On the other hand, the French PHARE trial attempted to build on the signal observed in the underpowered but encouraging FinHer study of 9 weeks of T and compared 6 months to 12 months. During the presentation at San Antonio I got lost in terms like “failed to prove lack of inferiority,” but just looking at the numbers, 6 months didn’t look quite as efficacious as 12, and the collective sentiment appears to be that we’ve done the right thing all along by following Dr Sledge’s orbital concept.
2. **Long-term impact of adjuvant trastuzumab**

In a brilliant and detailed analysis presented to the FDA in early 2005, the late NSABP statistician Dr John Bryant proposed that combining the data from 2 ongoing simultaneous adjuvant T trials (NSABP-B-31 and NCCTG-N9831) not only was feasible but also would help to obtain a quicker answer for patients, particularly as clinicians in practice grew increasingly uncomfortable holding the line at not using this relatively nontoxic agent with such a great likelihood of success. The FDA agreed with this premise, and later that year I had the pleasure of interviewing the NSABP’s Dr Edward Romond just moments after his presentation to the ASCO multitudes of this combined data set. During this memorable conversation Dr Romond’s voice was tremulous with emotion as he recounted for our audio audience the amazing history leading to that moment.

Dr Romond was again center stage in San Antonio, presenting the 10-year survival data from that landmark combined effort. The data reveal that the effects of treatment were similar regardless of ER status (this was also seen in HERA) and the survival benefit was still maintained although somewhat attenuated due to crossover to T once the data were released (20% crossover in the NSABP/NCCTG data and an unprecedented 52% in HERA). However, the profound impact of this advance can be understood from a different perspective when we consider the final numbers from this analysis of 4,046 patients: 391 vs 227 patients with distant recurrence; 381 vs 234 deaths from breast cancer; 206 vs 137 deaths among patients with ER and/or PR-positive tumors; 212 vs 149 deaths among patients with ER and PR-negative tumors.

3. **The way forward? Initial evidence suggesting a potential future role for immune checkpoint inhibitors combined with anti-HER2 agents**

As this first adjuvant HER2 chapter closes, others on the horizon will soon open, and when one asks investigators which current study or concept seems most promising, the first response is quite frequently the classically straightforward but immensely interesting APHINITY trial comparing adjuvant chemotherapy/T with or without the HER2 dimerization inhibitor pertuzumab. The enthusiasm for this compelling concept is partially related to prior data from the Phase II NeoSphere trial presented by Dr Luca Gianni, which demonstrated a marked increase in pathologic CRs when pertuzumab was added to chemotherapy/T in the neoadjuvant setting.

As in many contemporary neoadjuvant trials, a critical component of NeoSphere was the collection and analysis of tumor tissue, and at San Antonio Dr Gianni presented thought-provoking findings that expression of immune-based biomarkers, including PD-1, PD-L1, CTLA-4 and others, may predict benefit from HER2-directed therapies. These hypothesis-generating data may open the door to a new frontier in which anti-HER2 therapy is combined with the immune modulators that are offering so much hope
in melanoma, renal cell carcinoma, lung cancer and other challenging neoplasms. It will be fascinating to compare the NeoSphere translational findings to those about to be presented with the very first oral breast cancer paper at the upcoming ASCO meeting by Dr Lisa Carey from a major CALGB neoadjuvant HER2 study that also includes extensive tissue correlates.

This concludes our annual San Antonio wrap-up. Keep an eye out for our upcoming pre-ASCO email/video program with highlights from a recent breast cancer clinical investigator Think Tank with more on these and other new data sets and trial concepts.

Neil Love, MD
Research To Practice
Miami, Florida
HERA: 2 Years versus 1 Year of Adjuvant Trastuzumab at 8 Years of Follow-Up

Presentation discussed in this issue

Goldhirsch A et al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. San Antonio Breast Cancer Symposium 2012;Abstract S5-2.

Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Edith A Perez, MD (1/17/13)
Background

- The results of the Phase III HERA trial previously showed that 1 year of adjuvant trastuzumab (T) after chemotherapy is associated with a significant clinical benefit compared to observation in HER2-positive early BC after a median follow-up of 4 years (Lancet Oncol 2011;12:236-44).

- After 2005, the HERA protocol was revised to focus on the secondary objective of the trial, the assessment of whether 2 years of adjuvant T was superior to 1 year.

- **Objective:** Evaluate whether 2 years of T is superior to 1 year after adjuvant chemotherapy in women with HER2-positive early BC after a median follow-up of 8 years.

---

Phase III HERA Study Design

**Eligibility (N = 5,102)**

Locally determined HER2-positive invasive early BC
Treated with surgery + (neo)adjuvant chemotherapy +/- RT
Centrally confirmed IHC 3+ or FISH+
LVEF ≥55%

*Observation*  
(n = 1,698)

Trastuzumab 1 y  
8 mg/kg-6 mg/kg  
q3wk  
(n = 1,703)

Trastuzumab 2 y  
8 mg/kg-6 mg/kg  
q3wk  
(n = 1,701)

* 885 pts (52.1%%) crossed over to trastuzumab after disclosure of first results in 2005

Landmark Analysis of 2 Years versus 1 Year of Trastuzumab

- Two interim analyses and 1 final analysis were planned for patients randomly assigned to T who remained disease free for at least 12 months from randomization.
  - n = 1,553 patients in 2-year arm
  - n = 1,552 patients in 1-year arm
- Final analysis was planned for 725 disease-free survival (DFS) events to obtain 80% power to detect a hazard ratio of 0.8.
- Current analysis was reported with 734 DFS events at a median follow-up of 8 years.


DFS with 2 Years versus 1 Year of T

<table>
<thead>
<tr>
<th>Patient subgroup</th>
<th>T (1 y) (n = 1,552)</th>
<th>T (2 y) (n = 1,553)</th>
<th>HR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 y</td>
<td>86.7%</td>
<td>89.1%</td>
<td>0.99</td>
<td>0.86</td>
</tr>
<tr>
<td>5 y</td>
<td>81.0%</td>
<td>81.6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 y</td>
<td>76.0%</td>
<td>75.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR-positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 y</td>
<td>89.6%</td>
<td>90.3%</td>
<td>1.05</td>
<td>0.67</td>
</tr>
<tr>
<td>5 y</td>
<td>82.9%</td>
<td>83.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 y</td>
<td>77.2%</td>
<td>76.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR-negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 y</td>
<td>83.8%</td>
<td>87.8%</td>
<td>0.93</td>
<td>0.51</td>
</tr>
<tr>
<td>5 y</td>
<td>78.9%</td>
<td>80.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 y</td>
<td>74.7%</td>
<td>75.4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Overall Survival with 2 Years versus 1 Year of T (All Patients)

<table>
<thead>
<tr>
<th></th>
<th>T (1 y) (n = 1,552)</th>
<th>T (2 y) (n = 1,553)</th>
<th>HR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 y</td>
<td>96.5%</td>
<td>97.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 y</td>
<td>91.4%</td>
<td>92.6%</td>
<td>1.05</td>
<td>0.63</td>
</tr>
<tr>
<td>8 y</td>
<td>87.6%</td>
<td>86.4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Adverse Events (AEs)

<table>
<thead>
<tr>
<th>AE</th>
<th>T (1 y) (n = 1,682)</th>
<th>T (2 y) (n = 1,673)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1 Grade 3/4</td>
<td>16.3%</td>
<td>20.4%</td>
</tr>
<tr>
<td>Primary cardiac*</td>
<td>0.8%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Secondary cardiac†</td>
<td>4.1%</td>
<td>7.2%</td>
</tr>
<tr>
<td>Fatal AE</td>
<td>1.1%</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

* NYHA Class III or IV, confirmed by cardiologist, LVEF <50% and ≥10% below baseline or cardiac death
† LVEF <50% and ≥10% below baseline, confirmed by repeat assessment, excluding patients with a primary cardiac endpoint

- The majority of cardiac endpoints occurred during trastuzumab administration and were reversible.

Author Conclusions

- No evidence of long-term benefit was observed with 2 years versus 1 year of trastuzumab when administered as sequential treatment after chemotherapy.
- Secondary cardiac endpoints and other AEs are increased in the 2-year trastuzumab arm.
- The majority of cardiac endpoints occurred during trastuzumab administration and were reversible.
- A transient DFS advantage for the 2-year arm in the hormone receptor-negative cohort highlights the need for long-term follow-up in trials investigating different durations of adjuvant trastuzumab.


Author Conclusions (Continued)

- Results of the HERA study at 8 years of median follow-up show sustained and statistically significant DFS and OS benefit for 1 year of trastuzumab versus observation in ITT analyses despite selective crossover (data not shown).
- 1 year of trastuzumab remains a standard part of adjuvant therapy for patients with HER2-positive early BC.
- Benefit for 1 year of trastuzumab, compared to observation, was shown across hormone receptor-positive and negative cohorts (data not shown).

Investigator Commentary: HERA — 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up

The HERA trial compared 2 years versus 1 year of trastuzumab or observation for patients with HER2-positive early breast cancer. The results of the HERA trial, along with data from the PHARE trial that compared 6 versus 12 months of trastuzumab, suggest that 1 year of trastuzumab should be the standard treatment for patients with HER2-positive early breast cancer.

The next question for adjuvant trastuzumab remains whether we can add other agents to improve outcome. It remains to be determined whether we can use dual anti-HER2 blockade or anti-HER2 blockade with anti-HER2 vaccines.

*Interview with Edith A Perez, MD, January 17, 2013*